Core Viewpoint - The article discusses the financial performance of Huitai Medical (688617) for the year 2025, highlighting a significant shift where net profit growth (21.91%) fell below revenue growth (25.08%) for the first time since the company's listing, indicating a potential change in profitability dynamics [2][3]. Financial Performance Summary - In 2025, Huitai Medical reported total revenue of 2.584 billion yuan, a year-on-year increase of 25.08%, and a net profit attributable to the parent company of 821 million yuan, up 21.91% [2]. - This marks the first instance where net profit growth is lower than revenue growth, contrasting with the previous four years where net profit growth consistently outpaced revenue growth [3]. Net Profit Margin Analysis - The net profit margin trajectory over the past five years shows a consistent increase from 23.1% in 2020 to 32.6% in 2024, but it declined to 31.8% in 2025, a drop of approximately 0.8 percentage points [5][6]. - If the net profit margin had remained at 32.6%, the expected net profit would have been around 842 million yuan, indicating a shortfall of approximately 21 million yuan in actual profits [6]. Operating Efficiency and Profit Conversion - Despite the decline in net profit margin, operating profit increased to 944 million yuan, reflecting a growth rate of 25.24%, which is slightly higher than revenue growth [8]. - The increase in non-operating expenses, taxes, and minority interests from approximately 80.54 million yuan in 2024 to about 123 million yuan in 2025 contributed to the reduced efficiency in converting operating profit to net profit [8]. Cash Flow and Investment Trends - The cash flow from investment activities reversed dramatically from a positive 582 million yuan in 2023 to a negative 618 million yuan in 2024, indicating a net change of nearly 1.2 billion yuan [10][11]. - The significant increase in non-current assets by 67% from 8.17 billion yuan in 2023 to 13.64 billion yuan in 2024 suggests a substantial investment in capacity expansion, particularly in the new production facilities for vascular intervention products [11]. Product Development and Market Strategy - Huitai Medical is focusing its R&D and sales expenditures on core products like PFA (Pulsed Field Ablation), which are crucial for market expansion and clinical validation [13]. - The company has recently launched several new products in the atrial fibrillation treatment market, indicating a strategic shift towards larger market opportunities [13]. Revenue Composition and Future Outlook - In the first half of 2025, revenue from electrophysiology products decreased to approximately 21%, the lowest since financial records began, while revenue from coronary access products grew significantly [14]. - The upcoming revenue contributions from PFA products are anticipated to be a key factor in reversing the declining trend in net profit margin and improving overall profitability [18].